Chief, Neurotology Branch
NIDCD, National Institutes of Health
Bethesda, MD, United States
Ronna Hertzano, M.D., Ph.D., is a surgeon-scientist specializing in ear disease diagnosis, treatment and hearing restoration. Her research lab focuses on preventing hearing loss and developing innovative hearing restoration strategies through multi-omic analyses to identify key regulators in inner ear development and pathways related to age- and noise-induced hearing loss, including sex-based differences. Her team has discovered critical transcription factors in inner ear development, potential therapies for acquired hearing loss, and Dr. Hertzano established the gEAR portal for omics data sharing in hearing research. Dr. Hertzano places a strong emphasis on mentorship and is dedicated to nurturing the next generation of researchers, clinicians, and clinician-scientists. She also holds prominent editorial roles, serving as an associate editor in Otology Neurotology, a section editor in Hearing Research, a member of the editorial board of JARO, and is the president-elect of the Association for Research in Otolaryngology (ARO).
Dr. Hertzano earned her M.D. and Ph.D. degrees from Tel Aviv University, Israel, and completed her residency training in Otolaryngology Head and Neck Surgery and Otology and Neurotology at the University of Maryland School of Medicine (UMSOM) in Baltimore. In February 2023, she assumed the role of Chief of the newly established Neurotology Branch at the NIDCD. While in this leadership position, Dr. Hertzano continues to maintain a part-time clinical practice at UMSOM as an adjunct clinical professor.
The Leading Edge: What's New in Hearing Research
Sunday, September 29, 2024
2:30 PM – 3:30 PM EDT
Disclosure(s):
faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.
Physician-Scientist Training in Otolaryngology: A Crucial Path to Advancement
Monday, September 30, 2024
9:30 AM – 10:30 AM EDT
Disclosure(s):
faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.